Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
FENC Stock Chart & Stats
$7.32
-$0.02(-0.33%)
At close: 4:00 PM EST
$7.32
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$4.68 - $9.92
Previous Close$6.08
Volume58.66K
Average Volume (3M)142.47K
Market Cap
$252.02M
Enterprise Value$201.41M
Total Cash (Recent Filing)$21.93M
Total Debt (Recent Filing)$18.09M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 24, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,139,973
10 Day Avg. Volume185,558
30 Day Avg. Volume142,475
Financial Highlights & Ratios
PEG Ratio3.19
Price to Book (P/B)-22.88
Price to Sales (P/S)2.83
P/FCF Ratio4.98
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue5.19
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda-54.30
Forecast
1Y Price Target
$15.00Price Target Upside104.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.66
Revenue Forecast (FY)$78.85M
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceA major cancer institute conducting a real-world study of PEDMARK in adolescent, young adult, and adult patients receiving cisplatin could expand the evidence base and support broader clinical adoption beyond pediatric use.
Guideline Recognition And Product UniquenessPEDMARK is the only approved treatment shown to reduce cisplatin-related hearing loss and is recognized in the National Comprehensive Cancer Network guidelines for adolescent and young adult patients, which could increase physician confidence and patient eligibility.
Profitability OutlookAnalyst expects that ending interest payments after debt redemption and maintaining a lean commercial model could support sustained profitability and attractive operating margins as sales expand.
Bears Say
Partnership And Intellectual Property RiskUncertainties in partner relationships and potential challenges to intellectual property protection could disrupt commercialization plans and reduce future licensing or collaboration value.
Regulatory Approval RiskInability to obtain approvals in additional territories could restrict market access and limit revenue growth opportunities.
U.S. Commercial Adoption RiskSlower-than-expected commercial uptake in the United States could delay revenue scale-up and postpone attainment of profitability milestones.
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $4.68 and its highest was $9.92 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $252.02M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Mar 24, 2026 which is today.
How were Fennec Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,139,973 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (104.92% Upside)
$15.00 (104.92% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.57%
12-Months-Change
Fundamentals
Return on Equity
117.12%
Trailing 12-Months
Asset Growth
-16.39%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Stock 12 Month Forecast
Average Price Target
$15.00
▲(104.92% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Ownership Overview
9.92% Insiders
4.60% Mutual Funds
― Other Institutional Investors
79.93% Public Companies and
Individual Investors